Ceftiofur

Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987. It is marketed by pharmaceutical company Pfizer as Excede.

It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.